Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

The following is a summary of “Evaluating the therapeutic potential of tofacitinib in Sjögren’s disease: a comprehensive ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Iron-dependent ferroptosis, a non-apoptotic cell death mechanism, is gaining attention for its role in immune suppression.

The trial is due to begin in the second quarter of this year and will include enrolment from the US and other nations.

When I started receiving treatment for follicular lymphoma, I wasn’t sure what to expect regarding treatment — and a lot of things were unexpected. I’ve heard that trauma doesn’t make people stronger, ...

Chugai Pharmaceutical has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular ...

Polycystic ovary syndrome (PCOS) represents a significant health concern for women of reproductive age, manifesting as a ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...

Follicular lymphoma is the ... earlier approvals for diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukaemia. Kymriah was the first CAR-T to reach the market in 2017, but was ...